Radiology Business May 3, 2024
Novartis on Thursday announced plans to acquire radiopharmaceutical firm Mariana Oncology for up to $1.75 billion.
The Swiss drugmaker said the deal will bolster its research infrastructure and clinical supply capabilities, with an eye toward improving oncologic care. Watertown, Massachusetts-based Mariana has a “robust” portfolio, with early development of drugs targeted at cancers of the breast, prostate and lung.
It’s also developing MC-339, an actinium-based radiopharmaceutical for small cell lung cancer.
“The acquisition of Mariana Oncology reflects our commitment to radioligand therapy as one of our company’s key technology platforms and strengthens our leadership in this field,” Fiona Marshall, president of biomedical research at Novartis, said May 2. “We are excited to work with the Mariana team to bring forward...
Today's Sponsors
Today's Sponsor